Inclusion Criteria:

- Patients must have previously treated (> 1 cycle prior therapy), active multiple
myeloma requiring treatment. Patients that have received >450 mg/m2 of prior
Adriamycin therapy are eligible, however, Adriamycin will be deleted from the DT PACE
regimen in these patients.

- Patients must have measurable disease defined as one of the following: serum
monoclonal protein >/= 1.0 mg/dl, OR urine monoclonal protein >/= 1.0 grams/24 hour,
OR >/= 20% bone marrow plasmacytosis.

- All necessary baseline studies for determining eligibility must be obtained within 35
days prior to registration.

- Patients must have a performance status of 0-2 based on SWOG criteria.Patients with
a poor performance status (3-4), based solely on bone pain, will be eligible.

- Patients must have a platelet count > or = 100,000/microliters. Patients with
platelet count < 100,000/microliters may be enrolled if it is felt to be due to
extensive marrow plasmacytosis. The study coordinator must be consulted and dose
modifications may apply.

- All patients must be informed of the investigational nature of this study and must
sign and give written informed consent in accordance with institutional and federal
guidelines.

Exclusion Criteria:

- Patients must not have received a prior autotransplant or allograft.

- Patients must not have significant co-morbid medical conditions or uncontrolled life
threatening infection.

- Patients with recent (< o= 6 months) myocardial infarction, unstable angina,
difficult to control congestive heart failure, uncontrolled hypertension, or
difficult to control cardiac arrythmias are ineligible. Ejection fraction by ECHO or
MUGA should be within the institutional normal range and must be performed within 42
days prior to registration.

- Patients must not have a history of chronic obstructive or chronic restrictive
pulmonary disease.Patients must have adequate pulmonary function studies > or = 50%
of predicted on mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) >
or = 50% of predicted. Patients unable to complete pulmonary function tests due to
myeloma related pain or fracture must have a high resolution CT scan of the chest and
must also have acceptable arterial blood gases defined as P02 greater than 70.

- No prior malignancy is allowed except for adequately treated basal cell or squamous
cell skin cancer, in situ cervical cancer, or other cancer for which the patient has
been disease free for at least three years. Prior malignancy is acceptable provided
there has been no evidence of disease within the three-year interval and there must
be no prior treatment with cytotoxic drugs that could potentially be assigned on this
treatment protocol.

- Pregnant or nursing women may not participate. Women of childbearing potential must
have a negative pregnancy documented within one week of registration. Women/men of
reproductive potential may not participate unless they have agreed to use an
effective contraceptive method.